Taiwan
· Delayed Price · Currency is TWD Lin BioScience Statistics
Total Valuation
Lin BioScience has a market cap or net worth of TWD 11.29 billion. The enterprise value is 8.62 billion.
| Market Cap | 11.29B |
| Enterprise Value | 8.62B |
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Lin BioScience has 82.73 million shares outstanding. The number of shares has increased by 6.24% in one year.
| Current Share Class | 82.73M |
| Shares Outstanding | 82.73M |
| Shares Change (YoY) | +6.24% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 20.26% |
| Owned by Institutions (%) | 1.90% |
| Float | 62.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.11 |
| P/TBV Ratio | 4.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -11.58 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.41 |
Financial Position
The company has a current ratio of 34.45, with a Debt / Equity ratio of 0.01.
| Current Ratio | 34.45 |
| Quick Ratio | 33.66 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -1,456.21 |
Financial Efficiency
Return on equity (ROE) is -28.66% and return on invested capital (ROIC) is -20.57%.
| Return on Equity (ROE) | -28.66% |
| Return on Assets (ROA) | -19.97% |
| Return on Invested Capital (ROIC) | -20.57% |
| Return on Capital Employed (ROCE) | -27.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -69.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +57.68% in the last 52 weeks. The beta is -0.10, so Lin BioScience's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | +57.68% |
| 50-Day Moving Average | 125.08 |
| 200-Day Moving Average | 128.96 |
| Relative Strength Index (RSI) | 54.50 |
| Average Volume (20 Days) | 317,107 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.46B |
| Pretax Income | -1.33B |
| Net Income | -744.27M |
| EBITDA | -1.45B |
| EBIT | -1.46B |
| Earnings Per Share (EPS) | -9.47 |
Balance Sheet
The company has 5.21 billion in cash and 33.99 million in debt, giving a net cash position of 5.17 billion or 62.55 per share.
| Cash & Cash Equivalents | 5.21B |
| Total Debt | 33.99M |
| Net Cash | 5.17B |
| Net Cash Per Share | 62.55 |
| Equity (Book Value) | 5.35B |
| Book Value Per Share | 36.31 |
| Working Capital | 5.20B |
Cash Flow
In the last 12 months, operating cash flow was -1.02 billion and capital expenditures -5.82 million, giving a free cash flow of -1.03 billion.
| Operating Cash Flow | -1.02B |
| Capital Expenditures | -5.82M |
| Free Cash Flow | -1.03B |
| FCF Per Share | -12.39 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Lin BioScience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.24% |
| Shareholder Yield | n/a |
| Earnings Yield | -6.59% |
| FCF Yield | -9.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |